Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.47 |
| ▸ | PDE4A | P27815 | 12/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3375192 | 0.85 | MAPT (0.69) | MAPTKDM4ETHRBPDE4DPDE4B | |
| SCHEMBL3373532 | 0.82 | MAPT (0.69) | MAPTKDM4ETHRBPDE4DPDE4B | |
| SCHEMBL8635918 | 0.77 | PDE4D (0.69) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL8633365 | 0.76 | PDE4D (0.67) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL3377465 | 0.74 | PDE4D (0.46) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL17003768 | 0.73 | PDE4D (0.50) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL127193 | 0.72 | PDE4D (0.39) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL681776 | 0.71 | PDE4B (0.53) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL1157303 | 0.71 | PDE4D (0.53) | PDE4DPDE4BPDE4APDE4C | |
| SCHEMBL6876750 | 0.71 | PDE4D (0.56) | PDE4DPDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324091-A1 | Pyrazolone Derivative | KOWA COMPANY, LTD. (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-2172458-A1 | PYRAZOLONE DERIVATIVE | Kowa Company, Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324091-A1 | Pyrazolone Derivative | SERPINE1, SERPINC1, TFPI | MAPT 2810/4885KDM4E 4172/4885THRB 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.